Encochleated Amphotericin B: Is the Oral Availability of Amphotericin B Finally Reached?

Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy

(2020) Faustino et al.   Pharmaceutics

Nanostructured cochleates: a multi-layered platform for cellular transportation of therapeutics

(2019) Pravin Shende et al.   DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY

Efficacy of Oral Encochleated Amphotericin B in a Mouse Model of Cryptococcal Meningoencephalitis

(2019) R. Lu et al.   mBio

1413. A Phase IIa Efficacy, Safety, Tolerability and Pharmacokinetic (PK) Study of Encochleated Amphotericin B in Patients with Mucocutaneous (Esophogeal, Oropharyngeal, Vulvovaginal) Candidiasis Who are Refractory or Intolerant to Standard Non-Intravenous Therapies

(2018) Lilian Kibathi et al.   Open Forum Infectious Diseases

The global problem of antifungal resistance: prevalence, mechanisms, and management

(2017) David S Perlin et al.   LANCET INFECTIOUS DISEASES

Antifungal and immunomodulatory activity of a novel cochleate for amphotericin B delivery against Sporothrix schenckii

(2016) A. Batista-Duharte et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity

(2013) Richard J. Hamill   DRUGS

Alteration in cellular viability, pro-inflammatory cytokines and nitric oxide production in nephrotoxicity generation by Amphotericin B: involvement of PKA pathway signaling

(2013) F. D. França et al.   JOURNAL OF APPLIED TOXICOLOGY

It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug

(2012) Ana C. Mesa-Arango et al.   Frontiers in Microbiology

In vitro activity of amphotericin B cochleates against Leishmania chagasi

(2011) Aretha Molina Sesana et al.   MEMORIAS DO INSTITUTO OSWALDO CRUZ

Amphotericin B: side effects and toxicity

(2009) Rafael Laniado-Laborín et al.   REVISTA IBEROAMERICANA DE MICOLOGIA